Healthcare Private Placement and M&A Transactions Review Week Ending September 8, 2024

Egenesis: The company raised $191 million of Series D venture funding in a deal led by Lux Capital on September 4, 2024. Fresenius Medical Care Ventures, Leaps by Bayer, DaVita, Eisai Innovation, Natco Pharma, ARCH Venture Partners, Khosla Ventures, Alta Partners, Farallon Capital Management, and Parkwood also participated in the round. The company is a developer of a gene editing and genome engineering platform for solid organ and therapeutic cell transplantation.

Superluminal Medicines: The company raised $120 million of Series A venture funding in a deal led by RA Capital Management on September 4, 2024. NVentures, Eli Lilly and Company, Cooley, Insight Partners, Gaingels, and Catalio Capital Management also participated in the round. The company is a developer of a generative biology medicine technology intended to accelerate drug discovery and development.

Circle Pharma: The company raised $90 million of Series D venture funding in a deal led by The Column Group on September 3, 2024. Nextech Invest and Euclidean Capital also participated in the round. The company is a developer of macrocycle therapies designed to be cell-permeable and to be delivered by multiple routes, including oral administration.

LightForce: The company raised $50 million of venture funding from Trinity Capital on September 4, 2024. The company is a developer of a customized 3D printed orthodontic bracket system designed to deliver patient-specific digital dental treatment.

Venova Medical: The company raised $30 million of Series B venture funding from KOFA Healthcare, Cadence Healthcare Ventures, and ShangBay Capital on September 4, 2024. Aphelion Capital, Catalyst Health Ventures Mirae Asset Capital, E-merge Capital Partners and other undisclosed investors also participated in the round. The company is a developer of vascular access systems intended to address the challenges associated with providing optimal care for patients that need hemodialysis.

InterShunt: The company raised $23.4 million of Series B venture funding from New Day Venture Capital and other undisclosed investors on September 6, 2024. The company is a developer of a proprietary catheter system designed to provide relief to people suffering from heart failure.

CoapTech: The company raised $11 million of venture funding from Ecphora Capital and New Day Venture Capital on September 7, 2024. The company is a developer of invasive surgical devices designed to offer point-of-care ultrasound procedures in hollow organs.

Hepta Medical: The company raised EUR 5.7 million of venture funding in a deal led by Bpifrance on September 4, 2024. M&L Healthcare Investments and Clery also participated in the round. The company is a developer of a flexible microwave ablation platform intended to introduce minimally invasive nonsurgical treatment for early lung cancer.

EnClear Therapies: The company raised an undisclosed amount of venture funding from Amgen Ventures, Tachyon Ventures, and The Brain Tumor Investment Fund on September 3, 2024. Bioverge Ventures, Founders Fund, Thiel Capital and The Sontag Foundation also participated in the round. The company is a developer of device-based therapies designed to treat neurological diseases.

MediQuant: The company received an undisclosed amount of development capital from Revelstoke Capital Partners on September 4, 2024. The company is a developer of a data life cycle management platform intended to serve individual health systems, hospitals, and physician practices.

TippingPoint Biosciences: The company raised an undisclosed amount of venture funding from Pediatric Brain Tumor Foundation, The Sontag Foundation and Yuvaan Tiwari Foundation on September 5, 2024. BrightEdge also participated in the round. The company is an operator of a drug discovery platform intended to identify treatments for diseases caused by defects in DNA packaging.

Ironshore Therapeutics / Collegium Pharmaceutical: The company was acquired by Collegium Pharmaceutical for $525 million on September 4, 2024. The company is a developer of proprietary drugs with delayed-release and extended-release formulations.

Sonio / Samsung Medison: The company was acquired by Samsung Medison, via its financial sponsor SBI Investment Korea Company, through a $92.7 million LBO on September 2, 2024. The company is a developer of an artificial intelligence-based fetal ultrasound software intended to analyze and diagnose congenital malformations.

Alphalytik Pharmaservice / CERTANIA Holding: The company was acquired by CERTANIA Holding, via its financial sponsors Greenpeak Partners, Summit Partners, and Unigestion, through an LBO on September 4, 2024 for an undisclosed amount. The company is an operator of pharmaceutical laboratory services.

Clairvoyant / Psyence Biomed: The company reached a definitive agreement to be acquired by Psyence Biomed for an undisclosed amount on September 6, 2024. The company is an operator of a biotechnology company intended to offer patients psychedelic therapy.

HealthPivots / Netsmart Technologies: The company was acquired by Netsmart Technologies, via its financial sponsors GI Partners and TA Associates Management, through an LBO on September 4, 2024 for an undisclosed amount. The company is a developer of a cloud-based healthcare data analytics and services platform.

KAT Robotics / Kyniska Robotics: The company was acquired by Kyniska Robotics for an undisclosed amount on September 3, 2024. The company is a developer of a surgical robotics firm intended to provide knee surgeons with a precise and repeatable surgical procedure.

LinkX Robotics / Kyniska Robotics: The company was acquired by Kyniska Robotics for an undisclosed amount on September 3, 2024. The company is a developer of knee ligament surgery robotic technologies.

Verismo Therapeutics / HLB innoVation: The company was acquired by HLB innoVation for an undisclosed amount on September 5, 2024. The company is a developer of cancer therapeutics designed to improve persistence and efficacy against solid tumor models.